Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 840009 10.3389/fphar.2021.840009 Pharmacology Retraction Retraction: microRNA-155 Modulates Hepatic Stellate Cell Proliferation, Apoptosis, and Cell Cycle Progression in Rats With Alcoholic Hepatitis via the MAPK Signaling Pathway Through Targeting SOCS1 Frontiers Editorial Office Retraction: Role of miR-155 in HSC Frontiers Editorial Office * Frontiers Media SA, Lausanne, Switzerland

Approved by: Angelo A. Izzo, University of Naples Federico II, Italy

 *Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org

This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology

 17 01 2022 2021 12 840009 20 12 2021 20 12 2021 Copyright © 2022 Frontiers Editorial Office. 2022 Frontiers Editorial Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Retraction of the Original Research Article microRNA-155 Modulates Hepatic Stellate Cell Proliferation, Apoptosis, and Cell Cycle Progression in Rats With Alcoholic Hepatitis via the MAPK Signaling Pathway Through Targeting SOCS1 by Liu, D., Han, P., Gao, C., Gao, W., Yao, X., and Liu, S. (2020). Front. Pharmacol. 11:270. doi:10.3389/fphar.2020.00270 microRNA-155 suppressor of cytokine signaling 1 mitogen activated protein kinase signaling pathway alcoholic hepatitis hepatic stellate cell proliferation and apoptosis 3

The journal and Chief Editors retract the April 7, 2020 article cited above.

Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. Given the concerns, and the lack of raw data, the editors no longer have confidence in the findings presented in the article.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have not responded to any correspondence regarding the retraction.